Plasma level monitoring of nasal salmon calcitonin in the rat by a heterogeneous two-site enzyme immunoassay

Journal of Clinical Laboratory Analysis

Volumn 11, Issue 3, 1997, Pages 129-131

  Nakamuta, Hiromichi ^a   Kohno, Takeyuki ^a   Ichikawa, Masaki ^a   Hoshino, Takashi ^a   Watabe, Kazuhito ^a   Koida, Masao ^a  

^a SETSUNAN UNIVERSITY   (Japan)

Author keywords

AUC; bioavailability; hypocalcemic effect; MRT

Indexed keywords

SALCATONIN;

ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; ENZYME IMMUNOASSAY; HYPOCALCEMIA; IMMUNOREACTIVITY; INTRANASAL DRUG ADMINISTRATION; MALE; NONHUMAN; OSTEOPOROSIS; PHARMACODYNAMICS; RAT;

ADMINISTRATION, INTRANASAL; ANALGESICS; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BONE DISEASES, METABOLIC; CALCITONIN; HYPOCALCEMIA; IMMUNOASSAY; MALE; RATS; RATS, WISTAR;

EID: 0031002093     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2825(1997)11:3<129::AID-JCLA2>3.0.CO;2-5     Document Type: Article

References (16)

1. Azria M: The Calcitonins: Physiology and Pharmacology. Karger, Basel, 1989.
2. Marcus R; Rational approaches to osteoporosis therapy. Adv Pharmacol 22:29-55, 1991.
3. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, German C: Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 82:1268-1274, 1988.
4. Overgaard K, Riis BJ, Christiansen C, Hansen MA: Effect of calcitonin given intranasally on early postmenopausal bone loss. Br Med J 299:477-479, 1989.
5. Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS: Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435-442, 1989.
6. Clissold SP, Fitton A, Chrisp P: Intranasal salmon calcitonin' a review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging. Drugs Agings 1:405-423, 1991.
7. Deftos LJ: Two-site immunoradiometric assay of intact salmon calcitonin. Clin Chem 38:2248-2286, 1992.
8. Kurose H, Seino Y, Shima M, Tanaka H, Ishida M, Yamaoka K, Yabuuchi H: Intranasal absorption of salmon calcitonin. Calcif Tissue Int 41:249-251, 1987.
9. Kohno T, Nakamuta H, Ichikawa M, Watabe K, Koida M: A noncompetitive enzyme immunoassay (hetero-two-site enzyme immunoassay) for salmon calcitonin: Determination of bioavailabihty of subcutaneous salmon calcitonin and its correlation with the hypocalcemic activity in rat. J Clin Lab Anal 10:91-97, 1996.
10. Ichikawa M, Nakamuta H, Hoshino T, Ogawa Y, Koida M: Antiosteopenic effect of nasal salmon calcitonin in type 1 osteoporotic rats: Comparison with subcutaneous dosing. Biol Pharm Bull 7:911-913, 1994.
11. Nitta T, Hoshino T, Koida M, Nakamuta H: Histomorphometrical evaluation of anti-osteopenic effect of nasal salmon calcitonin in a Type 1 osteoporotic model of rats. Biol Pharm Bull 19:214-216, 1996.
12. Gitelman HJ: An improved automated procedure for the determination of calcium in biological specimens. Anal Biochem 18:521-531, 1976.
13. Yamada K, Nakagawa T, Uno T: Statistical moments m pharmacokinetics. J Pharmacokin Biopharm 6:547-558, 1978.
14. Riegelman S, Collier P: The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokin Biopharm 8:509-534, 1980.
15. Fenton AJ, Martin TJ, Nicholson T: Long-term culture of disaggregated rat osteoclast: Inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PTHrP(107-139). J Cell Physiol 155:1-7, 1993
16. Hoshino T, Nakamuta H, Ichikawa M, Koida M: Influence of osteostatin on osteoclast morphology. Jpn J Pharmacol 64:Suppl. I 289P, 1994.